Armata Pharmaceuticals FY2024 EPS Boosted by HC Wainwright

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Investment analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Armata Pharmaceuticals in a report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.95) for the year, up from their previous forecast of ($1.02). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2024 earnings at ($0.35) EPS and FY2025 earnings at ($1.70) EPS.

Armata Pharmaceuticals Stock Down 11.2 %

Shares of Armata Pharmaceuticals stock opened at $1.99 on Monday. The stock has a market capitalization of $72.00 million, a price-to-earnings ratio of -1.23 and a beta of 0.80. Armata Pharmaceuticals has a twelve month low of $1.93 and a twelve month high of $4.48.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.